Literature DB >> 33829334

Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery following chemo-/radiotherapy.

Takashi Kokumai1, Shuichi Aoki2, Masamichi Mizuma1, Shimpei Maeda1, Hideo Ohtsuka1, Kei Nakagawa1, Takanori Morikawa1, Fuyuhiko Motoi3, Takashi Kamei1, Michiaki Unno1.   

Abstract

PURPOSE: To clarify the prognostic value of the preoperative nutrition status of patients undergoing conversion surgery (CS) for initially unresectable pancreatic adenocarcinoma (UR-PA).
METHODS: The subjects of this retrospective study were 41 consecutive patients with initially UR-PA treated with chemo-/radiotherapy and subsequent CS between 2007 and 2014, at Tohoku University Hospital. The preoperative Glasgow Prognostic Score (GPS) was 0, conveying normal nutrition, in 25 patients (N group) and 1-2, conveying malnutrition, in 16 patients (M group). The clinicopathological factors influencing overall survival were defined by uni- and multivariate analyses.
RESULTS: The M group had a significantly worse prognosis than the N group (median overall survival (mOS) 9.6 vs 40.7 months, p = 0.001). Multivariate analysis identified a GPS of 1-2 as an independent predictor of worse prognosis [hazard ratio (HR)3.437, p = 0.032], followed by CA19-9 elevation before CS (HR4.089, p = 0.012) and pathological lymph node metastases (HR2.314, p = 0.046). Patients who maintained a favorable nutritional status (GPS 0) during preoperative treatment had a significantly better prognosis, whereas those whose nutritional status deteriorated (elevated to GPS 1-2) had poorer survival (mOS 40.7 vs. 9.7 months, p = 0.003)
CONCLUSION: Preoperative malnutrition status (GPS 1-2) is considered an independent predictor of a worse prognosis for patients undergoing CS for initially UR-PA.
© 2021. Springer Nature Singapore Pte Ltd.

Entities:  

Keywords:  Conversion surgery; Inflammation-based score; Pancreas adenocarcinoma

Mesh:

Year:  2021        PMID: 33829334     DOI: 10.1007/s00595-021-02279-5

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  41 in total

Review 1.  Pancreatic cancer treatment: better, but a long way to go.

Authors:  Robert J Torphy; Yuki Fujiwara; Richard D Schulick
Journal:  Surg Today       Date:  2020-05-30       Impact factor: 2.549

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.

Authors:  G Lakatos; A Petranyi; A Szűcs; L Nehéz; L Harsanyi; P Hegyi; G Bodoky
Journal:  Pathol Oncol Res       Date:  2017-01-06       Impact factor: 3.201

4.  Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.

Authors:  Ulrich Nitsche; Patrick Wenzel; Jens T Siveke; Rickmer Braren; Konstantin Holzapfel; Anna M Schlitter; Christian Stöß; Bo Kong; Irene Esposito; Mert Erkan; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Ann Surg Oncol       Date:  2015-09-08       Impact factor: 5.344

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

6.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.

Authors:  Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia
Journal:  Lancet Oncol       Date:  2013-12-05       Impact factor: 41.316

7.  Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).

Authors:  Fuyuhiko Motoi; Tomoo Kosuge; Hideki Ueno; Hiroki Yamaue; Sohei Satoi; Masayuki Sho; Goro Honda; Ippei Matsumoto; Keita Wada; Junji Furuse; Yutaka Matsuyama; Michiaki Unno
Journal:  Jpn J Clin Oncol       Date:  2019-02-01       Impact factor: 3.019

8.  Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?

Authors:  Isabella Frigerio; Paolo Regi; Alessandro Giardino; Filippo Scopelliti; Roberto Girelli; Claudio Bassi; Stefano Gobbo; Paolo Tinazzi Martini; Paola Capelli; Mirko D'Onofrio; Giuseppe Malleo; Laura Maggino; Elena Viviani; Giovanni Butturini
Journal:  Ann Surg Oncol       Date:  2017-05-17       Impact factor: 5.344

9.  National failure to operate on early stage pancreatic cancer.

Authors:  Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

10.  Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).

Authors:  Marie Robert; Marta Jarlier; Sophie Gourgou; Françoise Desseigne; Marc Ychou; Olivier Bouché; Beata Juzyna; Thierry Conroy; Jaafar Bennouna
Journal:  Oncology       Date:  2017-10-06       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.